I
nflammatory bowel disease (IBD) often affects women in their reproductive age, and disease incidence is increasing globally. 1 Active disease negatively impacts nutrient absorption and quality of life, and it increases the risk of adverse pregnancy outcomes such as preterm delivery and intrauterine growth retardation. 2, 3 Validated clinical tools to monitor disease activity during pregnancy are warranted to optimize treatment and overall patient care and to minimize the risk of adverse pregnancy outcomes. 4 The physiological changes occurring during pregnancy may mimic symptoms of IBD, and this could lead to unnecessary escalation of medical therapy. 5 Also, the clinical evaluation of abdominal complications in IBD may be compromised during late pregnancy. 6, 7 In nonpregnant patients with IBD, endoscopic evaluation is considered the gold standard in monitoring disease activity. 8 In case of small bowel Crohn's disease (CD) radiography or capsule endoscopy is needed in assessment of disease activity. 9, 10 For safety reasons, international guidelines recommend that lower intestinal endoscopy should only be performed in pregnant women if there is a strong indication, and preferably during the second trimester. 2, 3, 11 Capsule endoscopy is contraindicated in pregnancy and radiologic procedures are usually limited to ultrasonography and in selected patients also magnetic resonance imaging to protect the fetus from radiation exposure. 3, 12 The use of clinical disease activity indices and inflammation biomarkers are integrated tools in the care of nonpregnant patients with IBD. [13] [14] [15] During pregnancy, however, clinical and laboratory markers are altered secondary to the physiological adaptation. 16 C-reactive protein (CRP) and white blood cell counts are increased compared with nonpregnant women. 16 Plasma concentrations of hemoglobin, iron, and transferrin and the iron-binding capacity all drop to a low but stable concentration during pregnancy. 16 Plasma albumin drops 10% to 30% and varies throughout pregnancy, partly due to hemodilution. 16 Clinical indices have been developed to describe disease activity in both CD and ulcerative colitis (UC). None of these have been validated in pregnant women. 17, 18 These clinical indices are not readily translated to pregnant women because several of the index components are affected by physiological changes during pregnancy. 5, 16 The physician global assessment (PGA) is typically used to guide therapeutic decisions, and it has been used in previous IBD studies. 19, 20 In a study of nonpregnant patients with IBD, where endoscopy served as the gold standard for assessing disease activity in 154 patients with UC, PGA performed better than laboratory biomarkers, such as CRP, hemoglobin, albumin, ferritin, and platelet count, and PGA was highly specific (97%), but not very sensitive (30%), as a marker of active inflammation. 19 Although informative, PGA is therefore insufficient to guide clinical decisions.
Fecal calprotectin (FC) is the most commonly used fecal biomarker of disease activity in IBD. 8 It is a sensitive marker of mucosal inflammation and correlates with both endoscopic activity and histological inflammation. 21, 22 A FC above 250 mg/g is a highly sensitive marker of endoscopic disease activity in both CD (94.1% sensitivity and 62.2% specificity) and UC (71.0% sensitivity and 100.0% specificity). 21 In longitudinal studies of patients with IBD in remission, FC predicts clinical relapse. 21, 23 Without endoscopy as a feasible clinical option, it is likely that the use of FC in pregnant patients with IBD adds to the PGA to serve as a surrogate marker of disease activity, but this remains to be investigated.
The aims of this study were to investigate FC concentrations in pregnant women with or without IBD and to determine whether FC correlates with PGA, CRP, and clinical disease activity indices during the 6 months preconception period, during each trimester of pregnancy, and during the first 6 months postpartum. We also aimed to investigate if PGA correlates with CRP and clinical disease activity indices during all 5 periods of investigation.
MATERIALS AND METHODS
This observational multicenter study was conducted at 8 tertiary hospitals in Denmark, Australia, and New Zealand from March 2012 to November 2014 as a part of the ERA study. 20 Pregnant women with IBD who received treatment with adalimumab (Humira) or infliximab (Remicade) were prospectively recruited in the study. Healthy pregnant women older than 18 years with no history of a gastrointestinal disorder or familial predisposition for IBD were prospectively recruited as controls from the North and Central Denmark Regions.
All eligible women with or without IBD were interviewed in the outpatient clinic or by videoconferencing. After giving birth, all women with IBD completed a structured online questionnaire. The questionnaire covered demographic factors, medical treatment, and disease activity before conception, during each trimester of pregnancy, and postpartum. All data were confirmed with the treating physician. Disease activity was assessed prospectively by a PGA and evaluated as either active or in remission during the 6 months period before conception, during each trimester, and in the first 6 months postpartum. Clinical disease activity was assessed by indices and validated in nonpregnant patients. The Harvey-Bradshaw Index (HBI) and the Simple Clinical Colitis Activity Index (SCCAI) were used to assess disease activity in CD and UC, respectively. 13, 15 CD was considered to be in remission if HBI was # 4 points. Mild, moderate, and severe activity in CD was equivalent to HBI scores of 5 to 7, 8 to 16, and $17, respectively. 13 UC was considered to be in remission if SCCAI was #2 points. Mild, moderate, and severe activity in UC was equivalent to SCCAI scores of 3 to 5, 6 to 11, and $12, respectively. 24 Disease activity was monitored prospectively, and HBI/SCCAI was documented at each outpatient visit in 37 (80%) of 46 women. In the remaining 9 (20%), HBI/SCCAI was calculated, using data from the medical record.
The FC concentration in stool samples was quantified using a commercially available sandwich ELISA kit with a detection range from 30 to 3600 mg/g. Results below the detection limit of 30 mg/g were documented as 0 mg/g, and results greater than 3600 were recorded as 3600 mg/g. Active disease was defined as an FC above 250 mg/g. 21 Peripheral blood was drawn to measure CRP before pregnancy, during each trimester of pregnancy, or in the postpartum period. Active disease was defined by CRP above 5.0 mg/ L. 25 Infection was ruled out by fecal cultures and clostridium difficile testing at the discretion of the treating physician.
Statistical Analysis
Frequency tables of major study variables were constructed for the total population and separately for women with CD and UC. Pearson's Chi-squared test or Fisher's exact test were applied for the comparison of these groups. Two-sample t tests of major study variables were constructed by type of IBD and PGA of disease activity. The correlation of 2 variables-either continuous, ordinal, or categorical-was assessed by a Spearman correlation coefficient. Fisher's exact test was used to evaluate if an FC cutoff concentration of 250 mg/g and a CRP cutoff concentration of 5 mg/L correlated with disease activity defined by PGA or the clinical disease activity indices, that is an HBI $ 5 or an SCCAI . 2. A P value below 0.05 was considered statistically significant. All analyses were performed using Stata version 13.0 (Stata Corporation LP, College Station, TX). 
ETHICAL CONSIDERATIONS

RESULTS
Of the 89 pregnant women with IBD recruited for the ERA study, 5 (5.6%) miscarried before gestational week 10, and 38 (42.7%) had no FC measurements performed before, during, or after pregnancy. This left 46 patients for analysis: 39 from Denmark, 5 from Australia, and 2 from New Zealand. A total of 174 fecal and 205 blood samples were collected from the patients with IBD before pregnancy, during each trimester of pregnancy, and in the postpartum period. Demographic and clinical details of the patients are shown in Table 1 . The rates of disease activity according to FC, PGA, CRP, and HBI/SCCAI are shown in Table 2 .
All the 21 pregnant controls recruited supplied a stool sample for FCP measurement. Three (14.3%) were in first trimester, 8 (38.1%) in second trimester, and 10 (47.6%) were in third trimester of pregnancy at FC analysis. The age and median gestational week of the controls were 32 years (range 24-37) and 26 weeks (range 9-40), respectively.
FC Concentrations in Pregnant Controls and IBD Women
In the 21 pregnant controls, the median FC was 0 mg/g (range 0-84) as compared to median 131 mg/g (0-3600) in all 98 samples from pregnant patients with IBD (P , 0.0001). The median FC in IBD women with clinically active disease defined by PGA was significantly higher than the median FC of women in remission at all timepoints as shown in 
CRP Concentrations in Pregnant IBD Women
Apart from the second trimester, no statistically significant variation in CRP was found among patients with IBD with clinically active disease and patients with IBD in remission defined by PGA: conception period (2. Significant differences between women with CD and UC: CD women had longer disease duration (P ¼ 0.006), and more UC than CD women were treated with 5-aminosalicylic acid (P ¼ 0.02). 
Correlations Between FC, PGA, CRP, and Clinical Disease Activity Indices
The correlations between FC concentration, PGA, CRP, and clinical disease activity indices are shown in Table 3 . FC concentration statistically significantly correlated with PGA in all 5 periods of investigation and with disease activity indices before pregnancy and during the postpartum period. There was no statistically significant correlation between FC concentration and disease activity indices in any of the trimesters of pregnancy. FC and PGA both correlated statistically significant with CRP in the second trimester, but no statistically significant correlation was found in the remaining 4 periods of investigation. No statistically significant correlation was found between clinical disease activity indices and CRP at any timepoint. A statistically significant correlation between clinical disease activity indices and PGA was found before pregnancy, in the third trimester, and the postpartum period, but there was no statistically significant correlation in first and second trimester of pregnancy.
When associations between PGA and CRP were found in the remaining 3 periods of investigation: conception period 59.0% (23/39) (P ¼ 0.31), third trimester 68.3% (28/41) (P ¼ 0.07), and the postpartum period 62.5% (25/40) (P ¼ 0.44).
DISCUSSION
This international multicenter study investigated for the first time FC as a marker of disease activity during pregnancy. Based on the analysis, we recommend the use of FC in combination with the PGA of disease activity as a combined tool to monitor disease activity in pregnant patients with IBD.
A novel observation was that the physiological changes which occur during pregnancy in healthy women did not affect FC concentrations. This is important because other biomarkers such as CRP, albumin, hemoglobin, and leukocyte counts change during pregnancy in both healthy women and patients with IBD. 16 This finding is in line with preliminary results from Hungarian and Canadian studies. 26, 27 As FC does not appear to be affected by the pregnancy per se, it has the potential to be used as a biomarker of intestinal inflammation during pregnancy.
With regard to the use of FC during pregnancy in patients with IBD, it was observed that the FC concentrations were significantly higher in patients with clinically active disease as judged by PGA than in patients in remission during the conception period, all 3 trimesters of pregnancy, and the postpartum period. This is in keeping with preliminary results from a Canadian study that investigated 17 women. 28 As highlighted in a recent nonsystematic review and a meta-analysis of prospective studies, the results of this study are also in concordance with several studies of FC as a predictor for clinical relapse among nonpregnant patients with IBD. 14, 29 This study is the first to demonstrate a strong correlation between the FC concentration and PGA of disease activity in the conception period, during all 3 trimesters of pregnancy, and the postpartum period. In accordance with the present findings before and after pregnancy, Meuwis and coworkers and Theede and coworkers found a statistically significant correlation between FC and clinical disease activity indices (Crohn's disease Activity Index and SCCAI) among nonpregnant patients with CD and UC. 30, 31 By contrast, FC did not correlate with clinical disease activity during any of the 3 pregnancy trimesters. The lack of correlation between FC and clinical disease activity indices during pregnancy may be explained by the effect that pregnancy has on the clinical components of the activity indices that change throughout pregnancy. 5, 16 As highlighted in a nonsystematic review, several studies in nonpregnant patients with IBD have found a strong correlation between FC and endoscopic disease activity. 14 Some studies indicate limitations in the ability of FC to accurately reflect mucosal inflammation. 25, 32 Nevertheless, crosssectional studies found that FC outperformed clinical activity indices to discriminate patients in remission from those with mild, moderate, or severe endoscopic appearance. 33, 34 Although limited by the likelihood that the PGA is partly based on evaluation of the FC concentration, these data suggest that a combination of PGA and FC is superior to using the clinical disease activity index in combination with FC in monitoring disease activity during pregnancy.
The applied FC cutoff value for prediction of clinical relapse varies between studies. 14 In a study of 126 patients with IBD, an FC above 250 mg/g correlated significantly with endoscopic disease activity in both CD (94.1% sensitivity and 62.2% specificity) and UC (71.0% sensitivity and 100.0% specificity). 21 To minimize the fetal exposure, withdrawal of biological therapy in pregnancy may be considered in patients who have been in remission for a year before pregnancy and during the first and second trimester of pregnancy. 2, 3 If this strategy is used it is important to predict which patients are suitable and which are at high risk of relapse. In the STORI cohort study of 115 nonpregnant patients with CD, an FC threshold of 250 mg/g was found to predict relapse in case of withdrawal of infliximab. 30 In this study, the FC threshold for active inflammation was therefore set to 250 mg/g. Similar to the findings in nonpregnant patients with IBD, a highly significant correlation was observed between FC with a cutoff greater than 250 mg/g and disease activity by PGA in all 3 trimesters of pregnancy, whereas a correlation between FC and clinical disease activity indices could only be found in the third trimester of pregnancy. 21, 30 Apart from during the second trimester, CRP did not correlate with either FC or PGA. Furthermore, CRP did not correlate with clinical disease activity indices at any timepoint. Previous studies reported that up to 25% of nonpregnant patients with CD with endoscopic activity had normal CRP concentrations. 35 During pregnancy, CRP usually increases secondary to the physiological adaptation. 16 Taken together, CRP seems inferior to FC as a biomarker of disease activity in pregnant patients with IBD.
This study has important limitations. First, it is an inherent limitation that we could not apply endoscopy as the gold standard to evaluate the degree of intestinal inflammation, although this will not be ethically possible in pregnant women with IBD in a study environment 2, 3 Second, intraindividual variability of FC is well documented. 36, 37 One stool sample for the measurement of FC was collected in each trimester. Therefore, intraindividual variability in pregnancy could not be assessed. Third, the treating physicians were not blinded to the FC concentrations, and the assessment of disease activity may in part have been based on the FC concentration, thereby creating an obvious correlation between the FC concentration and PGA. With the restricted access to endoscopy and imaging and the limited validity of clinical disease indices in pregnant patients with IBD, FC may eventually be the most reliable objective marker of disease activity to support clinical decisions.
In conclusion, the assessment of disease activity during pregnancy using FC, PGA, or clinical disease activity indices alone seems insufficient. The physiological changes that occur during pregnancy seem not to affect FC, and there is a strong correlation between FC and PGA during pregnancy. The combined use of FC and PGA may prove to be the optimal way to assess disease activity during pregnancy in women with IBD, being superior to other biomarkers and clinical disease activity indices which are affected by the physiological changes in pregnancy. Further research is warranted to confirm these results.
